Very good news about the extension of the exclusivity period until 10/29 and that negotiations w/ the commercial stage wound care company for an ESS joint venture are still ongoing. Look, we all know that ESS and Elto are worth far more than the non-existent market cap ($2M) for this company. Sounds to me like the R/S is also getting postponed for now so that Gerald can hopefully land a partnership for ESS with a larger player (maybe Malinckrodt...ESS and Stratagraft are complimentary) to get the Phase 2 with the U.S. Army up and running